Abstract: To further enhance chimerism, 229 primary allograft recipients have received perioperalive intravenous infusion of a single dose of 3 to 6 X 10 8 unmodified donor-hone marrow (BM) ceUslkg body weight. In addition, 42 patients have heen accrued in a concurrent protocol involving multiple (up to three) sequential perioperative infusions of 2 X 10 8 BM cells/kglday from day 0-2 posttransplantation (PTx). Organ recipients (n = 133) for whom BM was not available were monitored as controls. The infusion of BM was safe and except for 50 (180/0), all study patients have optimal graft function. Of the control patients, allografts in 30 (23%) have heen lost during the course of follow-up. The cumulative risk of acute cellular rejection (ACR) was statistically lower in the study patients compared with that of controls. It is interesting that, 62O/c of Bolf-augmented heart recipients were free of ACR (Grade 2= 3A) in the fust 6 months PTx compared to controls. The incidence of obliterative hronchiolitis was also statistically lower in study lung recipients (3.8o/c) compared with the contemporaneously acquired controls (31 %). The levels of donor cell chimerism were at least a log higher in the peripheral blood of majority of the study patients compared with that of controls. The incidence of donor-specific hyporeacth;ty. as determined by one-way mixed leukocyte reaction, was also higher in those B)I-au~ented liver, kidney. and lung recipients that could be evaluated compared to controls. J. Leukoc. Bioi. 66: 310-314: 1999. 
INTRODUCTION
first documented the induction of donor-specific tolerance (OST) to transplanted allografts in rodents. In human recipients of bone marrow (B\1 I. this outcome was first documented by 'lathe et al. [2] 4Q . donor leukocytes (i.e. chimerism) in the tissues of long-term functioning organ allograft recipients prompted us to conclude that these cells may playa seminal role in graft acceptance [3, 4] . This hypothesis is supported by the observation that. similar to that of microorganisms. rejection or acceptance (tolerance) of transplanted allografts may be governed by the migration and localization of the antigen [5] . The idea of this trial came from the realization that the BM-derived leukocyte component of whole organs (commonly called passenger leukocytes) begins to migrate ubiquitously within a few minutes after transplantation and that these donor cells survive and constitute a small second cell population that is capable of defending itself against the immunological system of the recipient [3, 4, 6] . We have postulated. in what has been called the two-way paradigm. that the eventual induction of mutual nonreactivity of the coexisting cell populations, each to the other. is the essential basis of allograft acceptance [3, 4, 6] . Based on these earlier findings. it was therefore hypothesized that. if successful. adjuvant perioperative infusion of donor BM to organ allograft recipients would culminate (in a relatively higher number of patients) in the induction ofDST resulting in reduced incidence of acute cellular rejection (ACR) and chronic rejection (CR). and would allow early weaning and/or withdrawal of nonspecific immunosuppression (IS).
MATERIALS AND METHODS

Patients and BM infusion
-\fler oblainlng inform",\ eon'enl. palienb wilh ,.",\·-Idge organ railur .. who haJ no e\"idt>nl'e of aeti\'e infection. disseminat.:t1 malignancy. or prefitnanl'\ wt'rt-' \Lbrevialiuns: O~T. ,mall bowel In = 161. and multi-organ In = 21 were also accruffi. These were patlt'nts for whom B~ cells were not a"ailable due to our inabIlII' to obtain con,.,.nt to retne,e ,ertebral bodies I\'BI from prospecti"e dlmof> '. Recipient ,"X Imale/female ratiol. follow-up. age at transplant. human l"u\;.oc·'1e antigen dispant'. and olher demographic parameters were comparable in patients in the stud, IB\l-augrn"nl<·dl and the control groups. BM cell, were har\'ested from the \B of the cada"enc donor;; bv a method de,crib"d pre\loush [6J. Immuno,uppre"ion wa< with tacrolimus and steroid: CelICept "a, administerffi to .53 stud, and 17 control patient;.. For steroid-resistanee ACR. an antHh'mlK'vte monoc'lonal antibodv IOKT31 WdO used. \0 induction therap' wa". emplo,ed.
In vitro monitoring
Delamination of chimerism
Genomic D\A wa;. isolated from recipient', peripheral blood leukocvte, IPBLI ",th a I)l.\amp Blood Kit (Qiagen Inc .. !'anla Clarita. CAl and quantitatt'd 'pt'Ctrophotometriealh. 0\.\ samples with OD'''''2H11 1.7-1.9 "prl' used for pohmerase chain reaction (PCR) amplifications. A )'-chrom""ome specific marker I Sty !(ene I was amplified using the following external primer pair~ in the fir;t round of PCR: SRY5.1. 5-GAATAITCCCGCTCTCCGG.\-3: SRY 3. The quantit,· of donor Imale) D\A in test samples was determined b,' comparing its band volume with the standard curve and a ratio of donor! recipient DNA was calculated: the levels of donor cell (chimerism) in each patient were subsequently deduced.
Ui.~d leukocne reaction (MLR)
Pre-and senall\' posllransplant (everv other month) monitoring of recipient's immune status was carried out bv evaluating the proliferative responses of their peripheral blood mononuclear cells (PBMCs) to mitogens (concanavalin A. ph\1ohema~glutinin). r,.call antigens itetanus toxoid). MLR. and limiting dilution assav, I LOA). These assays a' well a. detailed studies of most of thes!' same patients have been described elsewher,. [6. 10] .
Statistical analysis
Lo~ rank and Fisher's exact test were used for statistical analysis.
RESULTS
Clinical outcome
[\('ept for that in liver allograft recipients. both single and multiple infusion of unmodified donor BM cells was safe. However. unlike single infusions. multiple infusions of BM -,,------------- 
Incidence of posttransplant Iymphoproliferative disease (PTLD) in Epstein-Barr virus-positive (EBV+) -EBV-BM recipients
There was some concern that adjuvant infusion of donor B~I in EBV+ --+ EB\' -urgan transplant recipients Olav increase both the incidence and the ,;everity of fYI'LD. thus obviating the beneficial effect of this therapy. concurrentl~ acquired pediatric controls \\t're diagnosed \\ ith this lesion: one died due to MSOF perhaps as a consequence of disseminated refractory PTLD (Table 1) . Among the adult organ allograft recipients. refractory PTLD was not encountered in the EBV+ --+ EBV-controls. whereas 2/5 (40%) study patients developed a refractory lesion that was unresponsive to initial weaning and/or withdrawal of IS ( 
Donor cell chimerism
As reported previously [6], BM-augmented patients had much higher (-92%) incidence of chimerism in their PBL compared with controls (-50%). This finding was consistent o\er the course of serial follow-up. Similarly. using semi-quantitative PCR, the levels of donor cell chimerism were found to be at least a log higher in the majority of the evaluated (male --+ female Tx recipients) BM-augmented patients compared with the controls. It is interesting that, as compared to single. multiple perioperative infusions of donor BM were associated with further elevation of levels of serially detennined chimerism in the PBL of organ allograft recipients.
In vitro immune reactivity
To undertake comparative anal~·sis. one-way MLR was perfonned serially PTx only in organ allograft recipients from whom pre-transplant blood was procured and donor splenocytes were available. [sing a previously outlined criterion [10] . higher incidence of donor-specific hyporeactivity (DSH) was encountered in those liver. kidney. and lung transplant recipients that were evaluated in this study compared with the controls (Table 21 . On the contrary, comparable levels of donor and third party-specific (data not shown) hyporeactivit\ were witnessed in stud~' and control heart. small bowel Idata not ~ho ..... n), kidney + pancreas, and multi-organ transplant Idata not shown) recipients (Table 2) . 
DISCUSSION
Heart B\1 augmented tsingle infusion
acquired immune responses against infectious agents were also MHC-restricted [12] . Because migration and localization of antigen was evidenced in both types of immune responses, it has been argued that in an otherwise naive host. this may be the seminal event resulting in the long-term acceptance of the allografts as well as the eradication of pathogenic infectious agents [5] . After T x, migration of alloantigens from the graft into the host's lymphoid and non-lymphoid tissues has been unequivocally demonstrated in long-term kidney and liver transplant recipients [3, 4] . The role of these ubiquitously localized donor cells in the induction of DST has been corroborated in numerous pre-clinical models of Tx tolerance [13] [14] [15] . Although the precise phenotype of these migraton' cells is as yet unknown, it was, however. determined that they were CD45+ cells of donor B\1 origin [3. 4, 13-15] . Accordingly, it was proposed that willful augmentation of this phenomenon in organ allograft recipients by perioperative infusion of BM cells obtained from either ('adaveric or living related donors. would greatlv reduce the incidence of ACR and CR as well as allow early weaning and/or withdrawal of nonspecific IS 13. 4. 6 ].
In 1992. we initiated a prospective elinical trial to affirm or refute this hypothesis in recipients of various organ allografts. To replicate the natural events that predictably transpire perioperativeiy, the recipients were not conditioned and the infused BM was not modified. Due to ethical and fiscal ('on('erns. this study was not randomized: ayailability (or otherwise) of YB from cadan'ric donors determined the accrual of a prospective recipient as a study or a control patient. Except for recipients of li\'er allografts. the infusion of single or multiple doses of donor B" was safe. In the liyer recipients. however. the perioperative infusion of multiple (but not single) doses of BM was associated with increased incidence of morbid G,·HD. thus prompting precocious termination of this latter protocol. To preyent untoward complications (with the exception of the first six lil"(:'f recipients). recipients of supposedly leukocyte-rich organs (i.e .. small howel. liYer. or multiyiscerall. receil'ed only a single holus infusion of donor BM immediately after organ Tx. On the contra~·. since l.pril 1996. recipients of all other organs han' receiyed multiple infusion!' of donor BM on 3 consecuti,e days (day 0-2) PTx.
During the course of follow-up. slightlY higher patient and graft loss has been documented in the control group compared with that of the study.l. !though being monitort-d. these parameters are not prima~' end-points of this study: the large number of patients that need to be acquirf'd in each organ group to conduct appropriate statistical analy"is is con"idered prohibitile .. \5 predicted. the cumulative risk of deyeloping .l.CR was ~tati5ti('ally lower in the B'I-augmented patients compared with the controls. It is interesting that this risk was lowered further in recipients of multiple BM infusion in whom correspondingly higher levels of donor cell chimerism were documented. Although admiHedl! longer {nHl}\\ -up is required to confirm this finding. it ne\·ertheJe.'i" .'iUppNts our earlier assf'rtion that establishment of stable ('himerism would result tin the majority of the patients) in the induction of DSH [3,4.6 ]. This benign effect of B\l infusion is perhaps best exemplified in heart allograft recipients in whom. d~plte reien,ion of donorspecific in l:itro immune reactivity. the incidence and severity of ACR was markedly lower in study patients compared with controls. Because an increased incidence of ACR is considered a precursor to the eventual evolution of CR. it eould be argued that BM augmentation would mitigate, if not abrogate. the development of the latter lesion in study heart allograft recipients.
In recipients of lung allografts. this predicted outcome has already been realized. Despite analogous incidence and severity of ACR, that of OB is remarkably lowt-r in patients in the study group compared with that of the controls. It is interesting that, when evaluated serially, BM-augmented lung recipients exhibited a higher incidence of DSH compared with the controls. Correspondingly, in those who are ;::: 1 year PTx, a higher number (l9o/c) of B\1-augmented lung allograft recipients have been taken off steroids as compart-d to the concurrently ace-rued controls (l19c l.
In coneiusion. infusion of donor BM was safe. with resultant increase in both the incidence and the levels of chimerism in the peripheral blood of organ allograft recipients. This latter finding translated into marked reduction in the incidence of ACR and CR with induction of DSH in BM-augmented liver. kidney. and lung recipients. l'nlike that in rodents and/or non-human primates. it is our contention that much longer follo\\-up would be required to realize the entire spectrum of predicted t-ffican of deliberate BM augmentation in human organ allograft re(,ipients. In light of our previous experienct-of deliberateh wt-aning IS (161, we have initiatt-d a similar prospectiye trial in BM-augmented and non-augmentt-d liver allograft recipients who exhibit stable graft function and are ;:::5 
